Related references
Note: Only part of the references are listed.Constitutional Methylation of the BRCA1 Promoter Is Specifically Associated with BRCA1 Mutation-Associated Pathology in Early-Onset Breast Cancer
Ee Ming Wong et al.
CANCER PREVENTION RESEARCH (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Diagnosis of Ovarian Carcinoma Cell Type is Highly Reproducible A Transcanadian Study
Martin Koebel et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2010)
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
Peter C. Fong et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression
Michael H. Roh et al.
MODERN PATHOLOGY (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
M. William Audeh et al.
LANCET (2010)
Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss
Blaise Clarke et al.
MODERN PATHOLOGY (2009)
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities
Joshua Z. Press et al.
BMC CANCER (2008)
Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma
C. Blake Gilks et al.
HUMAN PATHOLOGY (2008)
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer
Junzo Hamanishi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways
Rong Wu et al.
CANCER CELL (2007)
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
E Sato et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Survival benefit for patients with advanced-stage transitional cell carcinomas vs. other subtypes of ovarian carcinoma after chemotherapy with platinum and paclitaxel
F Kommoss et al.
GYNECOLOGIC ONCOLOGY (2005)
Pathology of ovarian cancers in BRCA1 and BRCA2 carriers
SR Lakhani et al.
CLINICAL CANCER RESEARCH (2004)
Transitional cell carcinoma of the ovary - A morphologic study of 100 cases with emphasis on differential diagnosis
JH Eichhorn et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2004)
Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry
BA Werness et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2004)
Lack of HIN-1 methylation defines specific breast tumor subtypes including medullary carcinoma of the breast and BRCA1 linked tumors
P Tisserand et al.
CANCER BIOLOGY & THERAPY (2003)
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
L Zhang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Immunoprofile of ovarian tumors with putative transitional cell (urothelial) differentiation using novel urothelial markers - Histogenetic and diagnostic implications
S Logani et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2003)
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer
HA Risch et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2001)
Clinicopathologic features of BRCA-linked and sporadic ovarian cancer
J Boyd et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2000)
Share Paper
